Skip to content

Mirror Therapy Education for Acute Stroke Patients

Effectiveness of Patient Education on Mirror Therapy to Improve Upper Extremity Function in Acute Stroke Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04542772
Enrollment
36
Registered
2020-09-09
Start date
2021-05-31
Completion date
2021-09-30
Last updated
2021-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Acute

Brief summary

In Canada, the number of stroke survivors is equivalent to the size of one of the four Atlantic Provinces. The incident rate of stroke has been increasing steadily since 1995. The majority of the stroke survivors lose upper extremity function, resulting in diminished activities of daily living (ADL). Many therapeutic interventions are recommended to improve upper extremity function or ADLs of stroke survivors, however, Mirror Therapy (MT), inexpensive intervention, can be self-administered by stroke survivors with intact cognition. Thus, the research question is whether a self-administered MT technique improves acute stroke patients' upper extremity motor function and recovery?

Interventions

OTHERMirror Therapy

Participants will receive the standard-of-care; multidisciplinary rehabilitation intervention based on their needs and tolerance, and will receive an additional 30 min of Mirror Therapy education. During Mirror Therapy education, the patients will be educated or shown how to perform MT and the patients will complete the recommended exercises on their own for 30 minutes/day for 5 days a week/ for 4 weeks. Standard Mirror Therapy Protocol will be followed.

Participants will receive the standard-of-care, multidisciplinary rehabilitation intervention based on their needs and tolerance.

Sponsors

NORTHERN ONTARIO ACADEMIC MEDICINE ASSOCIATION (NOAMA)
CollaboratorUNKNOWN
Health Sciences North Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Admitted with diagnosis of stroke with onset within two weeks * Medically stable * Able to follow directions * No severe cognitive impairments that could interfere with patient participation * Consent to treatment by patient * Alpha-Functional Independence Measure (Alpha-FIM) score of \> 40

Exclusion criteria

* Medical instability * Lack of motivation * Recurrent/ chronic stroke * Recent upper extremity musculoskeletal injuries with movement restrictions * Receptive or global aphasia * Delirium * Unilateral neglect * Visual field deficiency.

Design outcomes

Primary

MeasureTime frameDescription
Fugl-Meyer Assessment scaleAssessment will be completed at 2 points: Pre-test assessment will be done within 48 hours of stroke admission and post-test assessment will be done at 4 weeks.Scores of \< 31 corresponded with 'no to poor' upper extremity capacity, 32 to 47 represented 'limited capacity', 48 to 52 represented 'notable capacity' and 53 to 66 represented 'full' upper extremity capacity.
Wolf Motor Function Test: Assessment will be completed at 2 points: Pre-test assessment will be done within 48 hours of stroke admission and post-test assessment will be done at 4 weeksAssess upper extremity function; maximum Score is 75; lower scores are indicative of lower functional levels.

Secondary

MeasureTime frameDescription
Modified Barthel Index: Assessment will be completed at 2 points: Pre-test assessment will be done within 48 hours of stroke admission and post-test assessment will be done at 4 weeksAssess Activity of Daily Living, Scores of \<15 usually represents moderate disability and \<10 usually represents severe disability.

Contacts

Primary ContactVenkadesan Rajendran, PhD
vrajendran@hsnsudbury.ca1-866-469-0822
Backup ContactPadma Puranam, MD
ppuranam@hsnsudbury.ca1-866-469-0822

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026